Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial

Bellmunt, Joaquim; Hussain, Maha; Gschwend, Jurgen E.; Albers, Peter; Oudard, Stephane; Castellano, Daniel; Daneshmand, Siamak; Nishiyama, Hiroyuki; Majchrowicz, Martin; Degaonkar, Viraj; Shi, Yi; Mariathasan, Sanjeev; Grivas, Petros; Drakaki, Alexandra; O'Donnell, Peter H.; Rosenberg, Jonathan E.; Geynisman, Daniel M.; Petrylak, Daniel P.; Hoffman-Censits, Jean; Bedke, Jens; Kalebasty, Arash Rezazadeh; Zakharia, Yousef; van der Heijden, Michiel S.; Sternberg, Cora N.; Davarpanah, Nicole N.; Powles, Thomas

Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial

Autor(en):

Bellmunt, Joaquim; Hussain, Maha; Gschwend, Jurgen E.; Albers, Peter; Oudard, Stephane; Castellano, Daniel; Daneshmand, Siamak; Nishiyama, Hiroyuki; Majchrowicz, Martin; Degaonkar, Viraj; Shi, Yi; Mariathasan, Sanjeev; Grivas, Petros; Drakaki, Alexandra; O'Donnell, Peter H.; Rosenberg, Jonathan E.; Geynisman, Daniel M.; Petrylak, Daniel P.; Hoffman-Censits, Jean; Bedke, Jens; Kalebasty, Arash Rezazadeh; Zakharia, Yousef; van der Heijden, Michiel S.; Sternberg, Cora N.; Davarpanah, Nicole N.; Powles, Thomas

Tübinger Autor(en):

Bedke, Jens

Erschienen in:

Lancet Oncology (2021), Bd. 22, H. 4, S. 525-537

Verlagsangabe:

Elsevier Science Inc

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1016/S1470-2045(21)00004-8

ISSN:

1474-5488